Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Which Biopharmas Are Best Positioned For Five-Year Growth?

Executive Summary

Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.

Advertisement

Related Content

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
AstraZeneca CEO Hopes A Post-Trump And Brexit World Won't Damage Pharma
Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
BioMarin Scores Patent Board Win; Sarepta To Appeal
Celltrion Gears Up For Phase III Trial For Biosimilar Of Roche’s Rituxan
Roche’s Master Plan: Perjeta Gains Early Breast Cancer Approval, Late-Stage Kadcyla Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097779

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel